Namzaric for Improving Cognitive Function in Cancer Survivors who Received Radiation Therapy to the Brain, SPiRiT Study

Inclusion Criteria

• Cancer survivors who received cranial irradiation including, but not limited to, primary brain tumor, brain metastases, lung cancer receiving prophylactic brain irradiation, long-term survivors of pediatric cancers
• Completed a course of fractionated partial brain irradiation or whole brain irradiation of at least 30 Gy more than 6 months prior to enrollment
• Age >= 18 years at the time of entry into the study
• Karnofsky performance score (KPS) >= 70 or Eastern Cooperative Oncology Group (ECOG) grade =< 2
• No imaging evidence of disease progression within 4 months of enrollment
• Life expectancy > 6 months
• Access to a smartphone, tablet, or computer with capability to utilize the mobile symptom-tracking application

Exclusion Criteria

• Active psychiatric illness
• Clinically significant renal disease or insufficiency at the time of screening
• History of severe liver disease or laboratory values for liver function tests > 2.5 times the upper limit of normal at screening
• Use of cognition-enhancing medications at the time of screening. If patients have used cognition-enhancing medications in the past, a wash-out period can be considered for screening of 8 weeks at the discretion of the principal investigator (PI)
• Allergy to Namzaric or any of the components of Namzaric
• Pregnancy